RUNX1-mediated repression of miR-24 promotes hepatic stellate cell activation and liver fibrosis by targeting the ALK4/Smad3 signaling pathway
Open Access
- 30 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 17, 1825784
Abstract
Background: Epigenetic mechanisms, including microRNAs (miRNAs), are increasingly recognized as crucial regulators of organ fibrosis. In this study, we investigated the role of miR-24 in hepatic stellate cell (HSC) activation and liver fibrosis. Methods: miR-24 expression was analyzed in carbon tetrachloride (CCl 4 )-induced liver fibrosis and activated HSCs using quantitative real-time PCR (qRT-PCR). Gain- and loss-of-function experiments of miR-24 were performed in vitro . Western blotting, qRT-PCR, 5-ethynyl-2′-deoxyuridine (EdU) staining, flow cytometry, luciferase reporter assays, bioinformatics analysis, and chromatin immunoprecipitation PCR (ChIP-PCR) were performed to examine the molecular mechanisms of miR-24. Serum miR-24 levels were measured in patients with liver cirrhosis and further analyzed by subgroup. Results: We observed significant downregulation of miR-24 in CCl 4 -induced liver fibrosis and activated HSCs. Functional assays showed that miR-24 overexpression markedly inhibited HSC activation and migration, whereas miR-24 inhibition had the opposite effects. Mechanistically, ALK4 was identified as a direct target of miR-24: miR-24 bound the 3′UTR of ALK4 mRNA, thereby suppressing Smad3 phosphorylation and downstream fibrosis-associated signaling pathways. Furthermore, the transcription factor RUNX1 was induced during HSC activation, and it transcriptionally repressed miR-24 expression. Clinically, serum miR-24 levels were significantly lower in patients with liver cirrhosis than in healthy controls and were negatively correlated with Child–Pugh grade. Conclusion: Our findings suggest that the RUNX1/miR-24/ALK4 axis plays a crucial role in HSC activation and migration. miR-24 may serve as a biomarker for liver fibrosis screening, representing a potential therapeutic target for anti-fibrotic intervention.Keywords
Funding Information
- National Natural Science Foundation of China (U22A20275)
- National Natural Science Foundation of China (82570722)
- National Natural Science Foundation of China (82470642)
This publication has 54 references indexed in Scilit:
- Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosisCellular and Molecular Life Sciences, 2026
- Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver DiseaseJAMA Network Open, 2025
- The Global Burden of Liver DiseaseClinical Gastroenterology and Hepatology, 2023
- microRNA-122 inhibits hepatic stellate cell proliferation and activation in vitro and represses carbon tetrachloride-induced liver cirrhosis in miceAnnals of Hepatology, 2022
- Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemiaCell Reports, 2021
- NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in MiceHepatology, 2019
- LncRNA Gm5091 alleviates alcoholic hepatic fibrosis by sponging miR‐27b/23b/24 in miceCell Biology International, 2018
- The Genetic Architecture of Diet‐Induced Hepatic Fibrosis in MiceHepatology, 2018
- Epigenetic reprogramming in liver fibrosis and cancerAdvanced Drug Delivery Reviews, 2017
- A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic ResponseCell, 2013